Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery

Oncoscience. 2023 Sep 20;10:38-43. doi: 10.18632/oncoscience.586. eCollection 2023.ABSTRACTRipretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced gastrointestinal stromal tumor (GIST) in patients who received prior treatment with three or more tyrosine kinase inhibitors. In this case report, we show the durable clinical benefit achieved in a patient with GIST by using ripretinib and repeated timely surgical resection of limited disease progression. The total time on ripretinib was 43 months which is longer than the current reported data from ripretinib clinical trials. Such approach for using multi-disciplinary disease management can improve the durability of response to tyrosine kinase inhibitors, including ripretinib, and associated clinical outcomes.PMID:37736254 | PMC:PMC10511119 | DOI:10.18632/oncoscience.586

Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Mohamed A Gouda Filip Janku Neeta Somaiah Kelly K Hunt Sireesha Yedururi Vivek Subbiah Source Type: research